Skip to main content
Figure 2 | Journal of Neuroinflammation

Figure 2

From: Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms

Figure 2

β-hydroxybutyric acid (BHBA) treatment improves the behavioral dysfunction of lipopolysaccharide (LPS)-induced Parkinson’s disease (PD) model rats. Rats were randomly grouped and then pretreated with BHBA (0.4, 0.8, or 1.6 mmol/kg/d) or vehicle 3 days before LPS injection and subsequently for 21 days after LPS injection (24 days in total). (A, B) The number of turns induced by apomorphine for the LPS-induced PD model rats after 2 and 4 weeks of BHBA administration. The results are expressed as the mean ± SD. *P <0.05 and **P <0.01 compared with the LPS-treated rats; and ## P <0.01 compared with the sham-operated control rats.

Back to article page